PledPharma develops new drugs that protect the body against oxidative stress – a potentially debilitating and sometimes life-threatening condition that can be caused by chemotherapy treatment and following acetaminophen (paracetamol) overdose. The company's most advanced project PledOx® reduces nerve damage associated with chemotherapy. A phase IIb study has been conducted and will serve as the basis for the continued phase III development. The drug candidate Aladote® is being developed to reduce the risk of acute liver failure associated with acetaminophen poisoning.
PledPharma (STO: PLED) is listed on Nasdaq First North
Company Details
- Founded
- -
- Address
- Stockholm
- Phone
- (468)679-7210
- in****@****arma.se
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- pledpharma.se
- HQ
- Stockholm
Pledpharma Ab Questions
Pledpharma Ab's helpline number is (468)679-7210
Pledpharma Ab's website is pledpharma.se
Pledpharma Ab's LinkedIn profile is https://se.linkedin.com/company/pledpharma-ab
Pledpharma Ab's industry is
Pharmaceutical Manufacturing
Pledpharma Ab's top competitors are
Atrogi,
Nutrinovate,
D. Carnegie & Co Ab,
Willuhn Consulting,
The African Chamber Of Commerce In Somaliland,
Fenix Healthcare Ab,
Conveija,
Clarvin Ab,
Wintzell & Fried Ab,
Mericon As.
Pledpharma Ab's support email address is info@pledpharma.se
Pledpharma Ab's categories are Pharmaceutical Manufacturing
Pledpharma Ab's founding year is 2006
